High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

BACKGROUND: Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. METHODS: We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in seven sites in So...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Lancet Infect Dis
Główni autorzy: Boeree, Martin J, Heinrich, Norbert, Aarnoutse, Rob, Diacon, Andreas H, Dawson, Rodney, Rehal, Sunita, Kibiki, Gibson S, Churchyard, Gavin, Sanne, Ian, Ntinginya, Nyanda E, Minja, Lilian T, Hunt, Robert D, Charalambous, Salome, Hanekom, Madeleine, Semvua, Hadija H, Mpagama, Stellah G, Manyama, Christina, Mtafya, Bariki, Reither, Klaus, Wallis, Robert S, Venter, Amour, Narunsky, Kim, Mekota, Anka, Henne, Sonja, Colbers, Angela, van Balen, Georgette Plemper, Gillespie, Stephen H, Phillips, Patrick P J, Hoelscher, Michael
Format: Artigo
Język:Inglês
Wydane: Elsevier Science ;, The Lancet Pub. Group 2017
Hasła przedmiotowe:
Articles
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5159618/
https://ncbi.nlm.nih.gov/pubmed/28100438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(16)30274-2
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy